找回密碼
 To register

QQ登錄

只需一步,快速開始

掃一掃,訪問微社區(qū)

打印 上一主題 下一主題

Titlebook: Immunotherapy of Hepatocellular Carcinoma; Tim F. Greten Book 2017 Springer International Publishing AG 2017 Hepatocellular carcinoma.live

[復(fù)制鏈接]
查看: 15407|回復(fù): 45
樓主
發(fā)表于 2025-3-21 18:33:51 | 只看該作者 |倒序?yàn)g覽 |閱讀模式
書目名稱Immunotherapy of Hepatocellular Carcinoma
編輯Tim F. Greten
視頻videohttp://file.papertrans.cn/463/462310/462310.mp4
概述Contributions from experts in the field.Provides insights into new therapies.Provide an overview over fundamental immunological questions in liver cancer and tumorimmunology
圖書封面Titlebook: Immunotherapy of Hepatocellular Carcinoma;  Tim F. Greten Book 2017 Springer International Publishing AG 2017 Hepatocellular carcinoma.live
描述.In this book we provide insights into liver – cancer and immunology. Experts in the field provide an overview over fundamental immunological questions in liver cancer and tumorimmunology, which form the base for immune based approaches in HCC, which gain increasing interest in the community due to first promising results obtained in early clinical trials. ??.Hepatocellular carcinoma (HCC) is the third most common cause of cancer related death in the United States. Treatment options are limited. Viral hepatitis is one of the major risk factors for HCC, which represents a typical “inflammation-induced” cancer..Immune-based treatment approaches have revolutionized oncology in recent years. Various treatment strategies have received FDA approval including dendritic cell vaccination, for prostate cancer as well as immune checkpoint inhibition targeting the CTLA4 or the PD1/PDL1 axis in melanoma, lung, and kidney cancer. Additionally, cell based therapies (adoptive T cell therapy, CAR T cells and TCR transduced T cells) have demonstrated significant efficacy in patients with B cell malignancies and melanoma. Immune checkpoint inhibitors in particular have generated enormous excitement a
出版日期Book 2017
關(guān)鍵詞Hepatocellular carcinoma; liver cancer; Immunotherapy; tumor immunology; Immune-based treatment
版次1
doihttps://doi.org/10.1007/978-3-319-64958-0
isbn_softcover978-3-319-87911-6
isbn_ebook978-3-319-64958-0
copyrightSpringer International Publishing AG 2017
The information of publication is updating

書目名稱Immunotherapy of Hepatocellular Carcinoma影響因子(影響力)




書目名稱Immunotherapy of Hepatocellular Carcinoma影響因子(影響力)學(xué)科排名




書目名稱Immunotherapy of Hepatocellular Carcinoma網(wǎng)絡(luò)公開度




書目名稱Immunotherapy of Hepatocellular Carcinoma網(wǎng)絡(luò)公開度學(xué)科排名




書目名稱Immunotherapy of Hepatocellular Carcinoma被引頻次




書目名稱Immunotherapy of Hepatocellular Carcinoma被引頻次學(xué)科排名




書目名稱Immunotherapy of Hepatocellular Carcinoma年度引用




書目名稱Immunotherapy of Hepatocellular Carcinoma年度引用學(xué)科排名




書目名稱Immunotherapy of Hepatocellular Carcinoma讀者反饋




書目名稱Immunotherapy of Hepatocellular Carcinoma讀者反饋學(xué)科排名




單選投票, 共有 0 人參與投票
 

0票 0%

Perfect with Aesthetics

 

0票 0%

Better Implies Difficulty

 

0票 0%

Good and Satisfactory

 

0票 0%

Adverse Performance

 

0票 0%

Disdainful Garbage

您所在的用戶組沒有投票權(quán)限
沙發(fā)
發(fā)表于 2025-3-21 23:04:38 | 只看該作者
板凳
發(fā)表于 2025-3-22 00:39:50 | 只看該作者
地板
發(fā)表于 2025-3-22 05:42:28 | 只看該作者
5#
發(fā)表于 2025-3-22 11:02:45 | 只看該作者
Glypican-3 as a Target for Immune Based Therapy in Hepatocellular Carcinoma,ulfate chain. The HN3 and HS20 antibodies inhibit Wnt/Yap signaling and suppress HCC cell growth. To improve anti-tumor efficacy, anti-GPC3 immunotoxins and CAR-T cell therapies have been developed. The Wnt-blocking HN3 immunotoxin is more potent than YP7 immunotoxin. With an engineered toxin, the H
6#
發(fā)表于 2025-3-22 15:15:56 | 只看該作者
Immune Suppressor Mechanisms in HCC,ytokines as well as cell surface molecules such as PD1/PD-L1 have been described. A better understanding of the immunosuppressive microenvironment in the liver will help better understand the development and growth of HCC and provide opportunities to specifically target mechanism leading to enhanced
7#
發(fā)表于 2025-3-22 19:31:32 | 只看該作者
8#
發(fā)表于 2025-3-23 00:44:52 | 只看該作者
9#
發(fā)表于 2025-3-23 02:34:08 | 只看該作者
10#
發(fā)表于 2025-3-23 09:01:14 | 只看該作者
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務(wù)流程 影響因子官網(wǎng) 吾愛論文網(wǎng) 大講堂 北京大學(xué) Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點(diǎn)評(píng) 投稿經(jīng)驗(yàn)總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學(xué) Yale Uni. Stanford Uni.
QQ|Archiver|手機(jī)版|小黑屋| 派博傳思國(guó)際 ( 京公網(wǎng)安備110108008328) GMT+8, 2026-1-26 01:30
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復(fù) 返回頂部 返回列表
镇雄县| 阿合奇县| 通榆县| 大悟县| 元阳县| 五家渠市| 寿宁县| 阳城县| 名山县| 襄城县| 湟中县| 蓬莱市| 高尔夫| 乳山市| 措美县| 抚顺县| 瑞昌市| 黎平县| 壶关县| 南漳县| 错那县| 军事| 西乌珠穆沁旗| 莎车县| 海林市| 大田县| 禹州市| 海盐县| 丹凤县| 明星| 富川| 迁西县| 新宁县| 泰兴市| 商水县| 湖南省| 美姑县| 水富县| 聂拉木县| 阳原县| 唐山市|